A new generation of high flex life polyurethane urea for polymer heart valve—Studies on in vivo biocompatibility and biodurability
Source abstract
Abstract
Abstract Development of new generation high flex life polyurethane urea (HFL18‐PU) with appropriate elastic modulus, biocompatibility, blood compatibility, resistant to calcification, and biodurability for the long‐term use as cardiac device is still a challenge. This study reports the development of a fully aliphatic, ether‐free physically cross‐linked and low elastic modulus (6.841 ± 0.27 MPa) polyurethane urea having in vivo biostability, in vivo biocompatibility and high flex‐life (721 ± 30 million cycles) that can satisfy the requirements for the fabrication of tri‐leaflet heart valve. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cardiac Valve Diseases and Treatments · Orthopaedic implants and arthroplasty · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Biomedical applications of polyurethanes: A review of past promises, present realities, and a vibrant future10.1177/088532829901400104 ↗
2. Lamba NMK · 1998
3. Cardiac valve replacement: A bioengineering approach
4. Evaluation of explanted polyurethane tri‐leaflet cardiac valve prostheses10.1016/S0022-5223(19)36257-9 ↗
5. 10.1002/(SICI)1097-4636(19990315)44:4<371::AID-JBM2>3.0.CO;2-I10.1002/(SICI)1097-4636(19990315)44:4<371::AID-JBM2>3.0.CO;2-I ↗
6. A new design for polyurethane heart valves
7. Report of AorTech International plc 15th December2000.
8. HuntJA RhodesNP ShortlandAP WilliamsDF.A quantitative evaluation of the soft tissue response to biostable polyurethanes Transactions of Sixth World Biomaterials Congress Vol II Hawai USA 2000.
9. 10.1002/(SICI)1097-0126(200001)49:1<88::AID-PI298>3.0.CO;2-710.1002/(SICI)1097-0126(200001)49:1<88::AID-PI298>3.0.CO;2-7 ↗
10. 10.1002/1097-4636(200107)56:1<144::AID-JBM1079>3.0.CO;2-D10.1002/1097-4636(200107)56:1<144::AID-JBM1079>3.0.CO;2-D ↗
11. 10.1016/S0142-9612(01)00106-510.1016/S0142-9612(01)00106-5 ↗
12. Shultz AR · 1966 · 331
13. Formation and elution of toxic compounds from sterilised medical products: Methylene dianiline formation in polyurethane10.1177/088532829501000102 ↗
14. 10.1021/bm010044f10.1021/bm010044f ↗
15. 10.1016/0142-9612(91)90008-X10.1016/0142-9612(91)90008-X ↗
16. Quantitative methods for in vitro cytotoxicity testing of biomaterials
17. 10.1002/jps.260057010210.1002/jps.2600570102 ↗
18. Biological reactivity tests in vivo.The United States Pharmacopiea USP 23 (United States Pharmacopia convention Inc.) Rock villa Maryland 1995 p1699–1703.
19. 10.1021/ma951386e10.1021/ma951386e ↗
20. 10.1021/ma60073a02210.1021/ma60073a022 ↗
21. 10.1071/CH0216810.1071/CH02168 ↗
22. 10.1016/0142-9612(95)98817-X10.1016/0142-9612(95)98817-X ↗
23. Philips WM · 1980 · 39
24. 10.1016/0142-9612(95)00242-110.1016/0142-9612(95)00242-1 ↗
25. 10.1002/jbm.82021020710.1002/jbm.820210207 ↗
26. Struik LCE · 1978
27. 10.1016/0032-3861(87)90037-110.1016/0032-3861(87)90037-1 ↗
28. 10.1002/jbm.82020020510.1002/jbm.820200205 ↗
29. Marchant RE · 1988 · 297
30. 10.1002/jbm.82024050810.1002/jbm.820240508 ↗
31. 10.1002/jbm.82026060910.1002/jbm.820260609 ↗
32. 10.1002/jbm.82025030610.1002/jbm.820250306 ↗
33. 10.1016/0142-9612(91)90008-X10.1016/0142-9612(91)90008-X ↗